DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT02476760

Completed

Incretin-based Drugs and Acute Pancreatitis

The Use of Incretin-based Drugs and the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes

Assets

Exenatide / Liraglutide

Listed sites

1

Recruiting sites

—

Enrollment

1,417,914

actual

Study population

Type 2 diabetes

Key I/E criterion

—

Primary endpoint

•Pancreatitis

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02476760
Org study IDQ13-06B

Timeline

Milestones

Study first posted2015-06-19estimated
Last update posted2016-11-03estimated
Study start2014-03 (month precision)
Primary completion2015-04actual (month precision)
Study completion2015-04actual (month precision)

Assets

Investigational agents

ExenatideLiraglutide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted
Sampling methodProbability sample

Study population text

In each jurisdiction, the investigators will assemble a base cohort including all patients with a first-ever prescription for a non-insulin anti-diabetic drug. Base cohort entry is defined as the date of prescription or dispensation of the first-ever non-insulin anti-diabetic drug. From this base cohort, a study cohort will be formed including all patients who initiated a new anti-diabetic drug class during the year in which incretin-based drugs entered the market in each jurisdiction or any time thereafter. Study cohort entry is defined by the prescription date of the newly-prescribed drug class.

Inclusion criteria

•Patients with a first-ever prescription for a non-insulin anti-diabetic drug, including biguanides, sulfonylureas, thiazolidinediones, DPP-4 inhibitors, GLP-1 analogs, alpha-glucosidase inhibitors, meglitinides or combinations of these drugs from the earliest availability of data at each site to the last date of availability of data.
•Patients with at least 1 year of history in the database.
•Patients at least 18 years of age.

Exclusion criteria

•Patients who died or left the cohort before the year the first incretin-based drug entered the market.
•Patients who never added-on or switched to a new anti-diabetic drug after incretin-based drugs entered the market up until June 30, 2014.
•Patients with a previous diagnosis of pancreatic cancer, those who underwent pancreatectomy, those with diagnoses of congenital defects of the pancreas, cystic fibrosis, lupus, or previous bariatric surgery, at any time prior to study cohort entry.
•Patients diagnosed with HIV or initiating HAART therapy before and at study cohort entry.
•Patients hospitalized for acute pancreatitis in the 30 days before study cohort entry.

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

1 endpoint
Primary/protocol endpoint

Hospitalization for acute pancreatitis

Time frame:Patients were followed from the date of study cohort entry until hospitalization for incident acute pancreatitis, censoring, or for up to 87 months.

Pancreatitis

time to event, event

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.